Protective efficacy of miR-155 encapsulated using MS2 bacteriophage-based virus-like particle (MS2-VLP) against viral hemorrhagic septicemia virus (VHSV) in olive flounder.

Abstract

MicroRNAs (miRNAs) play important roles in the antiviral immunity of teleosts; however, their use as vaccines is limited by instability and delivery challenges. This study developed an MS2 bacteriophage virus-like particle (MS2-VLP) to encapsulate precursor miR-155, which has been reported to exhibit antiviral activity against viral hemorrhagic septicemia virus (VHSV). Recombinant MS2-VLP-miR-155, expressed in Escherichia coli, demonstrated a uniform 27 nm morphology, along with resistance to nuclease degradation. In addition, it remained stable under various temperature exposure, long-term storage, and repeated freeze-thaw cycles. In immunization trials, the miR-155-containing MS2-VLP group exhibited greater protective efficacy against VHSV challenge than miRNC-containing MS2-VLP and PBS control groups. At a challenge dose of 1 × 10 PFU/fish, cumulative mortality was significantly lower in the miR-155-containing MS2-VLP group (26 %) than in the PBS (80 %) and miRNC-containing MS2-VLP (66.6 %) groups. Furthermore, mature miR-155 was significantly detected in kidney tissue 3 days post-immunization, thereby confirming successful in vivo delivery and processing of the precursor. Collectively, these findings demonstrate that MS2-VLPs are a stable and effective platform for functional miRNA delivery in teleosts, with potential applications in the development of miRNA-based vaccines for aquaculture.